Lynparza Better Than Standard Chemo for HER2-Neg Mets w BRCA

Options
Moderators
Moderators Member Posts: 25,912
edited June 2017 in Genetic Testing

Lynparza Better Than Standard Chemotherapy for HER2-Negative Metastatic Breast Cancer in Women With BRCA Mutations
June 15, 2017

A study found that Lynparza improved progression-free survival by about 3 months in women diagnosed with metastatic, HER2-negative breast cancer who had a BRCA1 or BRCA2 mutation. Read more...

Categories